Pamela Pierce Palmer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Pamela Pierce Palmer has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Guo-Xi Xie
Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA 94143, USA
3 shared publicationsChristian Pietruck
Department of Anesthesia and Perioperative Care, University of California, Box 0464, Room S-455 513 Parnassus Avenue, San Francisco, CA 94143, USA
2 shared publicationsKumi Moriyama
2 shared publicationsLong-Chuan Yu
Laboratory of Neurobiology, College of Life Sciences, Peking University, Beijing 100871, P.R. China
2 shared publicationsThomas Meuser
Department of Anesthesia and Perioperative Care, University of California, Box 0464, Room S-455 513 Parnassus Avenue, San Francisco, CA 94143, USA
2 shared publicationsA Gabriel
Department of Anesthesia and Perioperative Medicine, University of California at San Francisco, 513 Parnassus Avenue, San Francisco, CA 94143-0464, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2012
- Published by SAGE Publications in Molecular Pain
- Vol. 8, 38
Molecular and Cellular Mechanisms of the Age-Dependency of Opioid Analgesia and Tolerance
The age-dependency of opioid analgesia and tolerance has been noticed in both clinical observation and laboratory studies. Evidence shows that many molecular and cellular events that play essential roles in opioid analgesia and tolerance are actually age-dependent. For example, the expression and functions of endogenous opioid peptides, multiple types of opioid receptors, G protein subunits that couple to opioid receptors, and regulators of G protein signaling (RGS proteins) change with development and age. Other signaling systems that are critical to opioid tolerance development, such as N-methyl-D-aspartic acid (NMDA) receptors, also undergo age-related changes. It is plausible that the age-dependent expression and functions of molecules within and related to the opioid signaling pathways, as well as age-dependent cellular activity such as agonist-induced opioid receptor internalization and desensitization, eventually lead to significant age-dependent changes in opioid analgesia and tolerance development.
- 1 January 2012
- Published by SAGE Publications in Molecular Pain
- Vol. 8, 38
Open AccessMolecular and Cellular Mechanisms of the Age-Dependency of Opioid Analgesia and Tolerance
The age-dependency of opioid analgesia and tolerance has been noticed in both clinical observation and laboratory studies. Evidence shows that many molecular and cellular events that play essential roles in opioid analgesia and tolerance are actually age-dependent. For example, the expression and functions of endogenous opioid peptides, multiple types of opioid receptors, G protein subunits that couple to opioid receptors, and regulators of G protein signaling (RGS proteins) change with development and age. Other signaling systems that are critical to opioid tolerance development, such as N-methyl-D-aspartic acid (NMDA) receptors, also undergo age-related changes. It is plausible that the age-dependent expression and functions of molecules within and related to the opioid signaling pathways, as well as age-dependent cellular activity such as agonist-induced opioid receptor internalization and desensitization, eventually lead to significant age-dependent changes in opioid analgesia and tolerance development.
- 1 February 2007
- Published by Elsevier in Journal of Molecular Biology
- Vol. 366 (2) , 349-365
How Regulators of G Protein Signaling Achieve Selective Regulation
- 1 February 2007
- Published by Elsevier in Journal of Molecular Biology
- Vol. 366 (2) , 349-365
How Regulators of G Protein Signaling Achieve Selective Regulation
- 1 June 2005
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 100 (6) , 1740-1745
Age-Dependent Opioid Escalation in Chronic Pain Patients
Rapid opioid dose escalation, possibly caused by tolerance, has been observed in some patients on daily opioid therapy, although clinically identifiable characteristics of these patients are unknown. In this retrospective chart review of 206 patients, we examined whether the age of the patient was related to opioid escalation. Initial starting doses of long-acting opioids were similar in younger patients (< or =50 yr; 49 +/- 3 mg/d oral morphine-equivalent dose) versus older patients (> or =60 yr; 42 +/- 3 mg/d). Younger patients reached a maximum dose of 452 +/- 63 mg/d over 15.0 +/- 1.3 mo, whereas older patients achieved a maximum dose of 211 +/- 23 mg/d over 14.4 +/- 1.5 mo (P < 0.0001). At the last clinic visit, younger-patient dosing averaged 365 +/- 61 mg/d, with older patients averaging 168 +/- 18 mg/d (P < 0.0001). Only older patients demonstrated a reduction in visual analog scale scores from start of opioid therapy until discharge from the clinic (6.9 +/- 0.3 to 5.6 +/- 0.3; P < 0.01). These clinical data suggest that age is an important variable in opioid dose escalation. Although factors other than opioid tolerance can result in dose escalation, it is possible that older patients may have a reduced rate of tolerance development.
- 1 June 2005
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 100 (6) , 1740-1745
Age-Dependent Opioid Escalation in Chronic Pain Patients
Rapid opioid dose escalation, possibly caused by tolerance, has been observed in some patients on daily opioid therapy, although clinically identifiable characteristics of these patients are unknown. In this retrospective chart review of 206 patients, we examined whether the age of the patient was related to opioid escalation. Initial starting doses of long-acting opioids were similar in younger patients (< or =50 yr; 49 +/- 3 mg/d oral morphine-equivalent dose) versus older patients (> or =60 yr; 42 +/- 3 mg/d). Younger patients reached a maximum dose of 452 +/- 63 mg/d over 15.0 +/- 1.3 mo, whereas older patients achieved a maximum dose of 211 +/- 23 mg/d over 14.4 +/- 1.5 mo (P < 0.0001). At the last clinic visit, younger-patient dosing averaged 365 +/- 61 mg/d, with older patients averaging 168 +/- 18 mg/d (P < 0.0001). Only older patients demonstrated a reduction in visual analog scale scores from start of opioid therapy until discharge from the clinic (6.9 +/- 0.3 to 5.6 +/- 0.3; P < 0.01). These clinical data suggest that age is an important variable in opioid dose escalation. Although factors other than opioid tolerance can result in dose escalation, it is possible that older patients may have a reduced rate of tolerance development.
- 1 April 2005
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 100 (4) , 1034-1042
RGS Proteins: New Players in the Field of Opioid Signaling and Tolerance Mechanisms
Nisms, and RGS proteins are now known to tightly regulate the G protein signaling cycle. RGS proteins contain GTPase-accelerating protein activity within their characteristic RGS domain and various other receptor signaling-related properties of their other functional domains. There have been more than 20 RGS proteins reported in the literature, and multiple RGS proteins have been shown to negatively regulate G protein-mediated opioid signaling, facilitate opioid receptor desensitization and internalization, and affect the rate at which opioid tolerance develops. Using RGS proteins as targets for future drug therapy aimed at modulating opioid effectiveness in both acute and chronic pain settings may be an important advance in the treatment of pain....
- 1 April 2005
- Published by Wolters Kluwer Health in Anesthesia & Analgesia
- Vol. 100 (4) , 1034-1042
RGS Proteins: New Players in the Field of Opioid Signaling and Tolerance Mechanisms
Nisms, and RGS proteins are now known to tightly regulate the G protein signaling cycle. RGS proteins contain GTPase-accelerating protein activity within their characteristic RGS domain and various other receptor signaling-related properties of their other functional domains. There have been more than 20 RGS proteins reported in the literature, and multiple RGS proteins have been shown to negatively regulate G protein-mediated opioid signaling, facilitate opioid receptor desensitization and internalization, and affect the rate at which opioid tolerance develops. Using RGS proteins as targets for future drug therapy aimed at modulating opioid effectiveness in both acute and chronic pain settings may be an important advance in the treatment of pain....
- 29 October 2004
- Published by Elsevier in Brain Research
- Vol. 1025 (1-2) , 67-74
Role of nociceptin in the modulation of nociception in the arcuate nucleus of rats
- 29 October 2004
- Published by Elsevier in Brain Research
- Vol. 1025 (1-2) , 67-74
Role of nociceptin in the modulation of nociception in the arcuate nucleus of rats
- 1 January 2004
- Published by Springer Nature in Inflammation Research
- Vol. 53 (2) , 66-71
Leukotrienes mediate 5-hydroxytryptamine-induced plasm extravasation in the rat knee joint via CysLT-type receptors
- 1 January 2004
- Published by Springer Nature in Inflammation Research
- Vol. 53 (2) , 66-71
Leukotrienes mediate 5-hydroxytryptamine-induced plasm extravasation in the rat knee joint via CysLT-type receptors
- 2 May 2002
- Published by Elsevier in Brain Research
- Vol. 945 (1) , 88-96
Involvement of endogenous opioid systems in nociceptin-induced spinal antinociception in rats
- 2 May 2002
- Published by Elsevier in Brain Research
- Vol. 945 (1) , 88-96
Involvement of endogenous opioid systems in nociceptin-induced spinal antinociception in rats
- 5 April 2001
- Published by Elsevier in Neuroscience
- Vol. 103 (4) , 1085-1092
Bi-directional modulation of 5-hydroxytryptamine-induced plasma extravasation in the rat knee joint by nociceptin
- 5 April 2001
- Published by Elsevier in Neuroscience
- Vol. 103 (4) , 1085-1092
Bi-directional modulation of 5-hydroxytryptamine-induced plasma extravasation in the rat knee joint by nociceptin
- 1 October 1999
- Published by Elsevier in Life Sciences
- Vol. 65 (21) , 2205-2213
Alternative exon splicing of cyclic AMP response element-binding protein in peripheral sensory and sympathetic ganglia of the rat
- 1 October 1999
- Published by Elsevier in Life Sciences
- Vol. 65 (21) , 2205-2213
Alternative exon splicing of cyclic AMP response element-binding protein in peripheral sensory and sympathetic ganglia of the rat